Načítá se...
Looking forward to new targeted treatments for chronic spontaneous urticaria
The introduction of omalizumab to the management of chronic spontaneous urticaria (CSU) has markedly improved the therapeutic possibilities for both, patients and physicians dealing with this disabling disease. But there is still a hard core of patients who do not tolerate or benefit from existing t...
Uloženo v:
| Vydáno v: | Clin Transl Allergy |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
BioMed Central
2017
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5223554/ https://ncbi.nlm.nih.gov/pubmed/28078079 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13601-016-0139-2 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|